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Introduction
Deorphanization of GPCRs remains an active area of research, 
especially considering that approximately 40% of all approved 
drugs for humans target only a small fraction of the GPCRome 
(1, 2). In addition to elucidating the pharmacology of orphan 
GPCRs, it is crucial to characterize the anatomical locations 
and physiological functions of these receptors in vivo. G pro-
tein–coupled receptor 182 (GPR182, formerly known as G10D 
or adrenomedullin receptor [ADMR]) (3, 4), is a class A orphan 
GPCR with very little known about its expression, function, reg-
ulation, or pharmacology. GPR182 is grouped within the chemo-
kine receptor family by phylogeny, with the atypical chemokine 
receptor 3 (ACKR3, formerly known as CXCR7 or RDC1) as its 
closest paralog, despite the two sharing a modest, less-than-30% 
sequence homology in mice and humans. GPR182 was previous-
ly considered a putative receptor for the multifunctional peptide 
adrenomedullin (4), however, these initial findings were not 
consistent among laboratories (5), and it was later shown that 
adrenomedullin signals through a different GPCR complex (6). 
Unfortunately, the former ADMR nomenclature is sometimes 
still used, which leads to confusion in the field. For example, 
GPR182 was reported to be expressed in numerous human pan-
creatic cancer cell lines, and knockdown of GPR182 in these 
cells decreased xenograft tumor growth, which the authors 
concluded was due to a loss of adrenomedullin signaling (7, 8). 
Anatomical expression profiling of the GPCRome demonstrat-
ed the relatively ubiquitous low expression of Gpr182 in most 
mouse tissues (9). More recently, Gpr182 was found to be highly 
expressed in developing murine and zebrafish endothelium and 
enriched in mammary tumor endothelium compared with nor-
mal mammary endothelium (10–12). Additionally, Gpr182 was 
identified among a group of factors that are significantly altered 
in a zebrafish model of myeloid leukemia (13). Thus, a signif-
icant advance of the current study is to map the expressional 
profile of Gpr182 using an in vivo mammalian reporter model, in 
which, in addition to the endothelium of numerous tissues, we 
observed expression within the gastrointestinal tract epithelia.
The epithelium of the gastrointestinal tract is one of the most 
dynamic tissues in the adult body and is primarily responsible for 
the absorption of dietary nutrients and also for fulfilling important 
endocrine, immune, and protective barrier functions. To maintain 
its proper functions, the intestinal epithelium must undergo contin-
uous turnover, with the entire small intestinal epithelium renewing 
every week in humans and in mice. This constant renewal is driv-
en by an active population of intestinal stem cells (ISCs) that are 
located at the base of the crypts of Lieberkühn, where they give 
rise to rapidly dividing daughter transit-amplifying progenitor cells 
that differentiate into the absorptive or secretory lineages respon-
sible for functions of the intestine (14–17). Current views hold that 
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Y)-box 9 (Sox9), our understanding of both of these ISC popula-
tions has drastically expanded over the past decade (19–26). It is 
evident that the activity and proliferation of these ISCs must be 
tightly controlled by numerous signaling pathways and redundant 
mechanisms in order to maintain homeostasis in the dynamic gut 
microenvironment (14, 27). Furthermore, oncogenic mutations 
specifically in ISCs can drastically enhance adenoma formation in 
mice (20, 28). Thus, defining the factors that regulate ISC prolifer-
ation and survival is critical in order to better understand ISC func-
tion during homeostasis, damage repair, and cancer and, hence, to 
better therapeutically target these ISCs.
2 distinct pools of ISCs exist in the intestinal epithelium: the crypt 
base columnar (CBC) ISCs, which are positioned between differen-
tiated Paneth cells and mediate normal homeostatic renewal, and 
“damage-resistant” ISCs, which act as reserve ISCs that are acti-
vated following injury (14, 15, 17, 18). With the discovery of numer-
ous ISC-specific markers including leucine-rich repeat contain-
ing G protein–coupled receptor 5 (Lgr5), leucine-rich repeats and 
Ig-like domains 1 (Lrig1), achaete-scute family bHLH transcription 
factor 2 (Ascl2), olfactomedin 4 (Olfm4), HOP homeobox (Hopx), 
telomerase reverse transcriptase (Tert), BMI1 proto-oncogene, 
polycomb ring finger (Bmi1), and SRY (sex-determining region 
Figure 1. Murine Gpr182 expression profile during development and adulthood. (A) Targeting vector of the Gpr182tm2a(KOMP)Wtsi/+ lacZ reporter mouse model 
(29, 62, 63). The GPR182 protein–coding region is shaded in pink. mGPR182, murine GPR182. (B) Whole-mount X-gal staining of E8 Gpr182lacZ/lacZ embryo. 
DA, dorsal aorta; VV, vitelline vein. (C) Optical projection tomography of whole-mount X-gal–stained WT and Gpr182lacZ/lacZ E13.5 embryos. X-Gal staining 
in Gpr182lacZ/lacZ E13.5 heart (D) and E17.5 lung, kidney, liver, yolk sac, and stomach, pancreas, and duodenum (E). Representative Gpr182 lacZ expression 
in adult heart (F), lung (G), kidney (H), liver (I), glandular stomach (J), and colon (K) stained with X-gal and/or β-gal (green). Sections were costained with 
DAPI (purple) and either the endothelial marker CD31 (F) or the podocyte marker podoplanin (PDPN) (H). X-Gal–stained sections were counterstained with 
eosin (F–H) or Neutral Red (D and I–K). Scale bars: 200 μm (B and D), 1 mm (C, E, and K), and 100 μm (F–J).
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with levels in Gpr182+/+ Cre controls (Supplemental Figure 1A). 
Like the Gpr182lacZ/lacZ mice, the Gpr182Δ/Δ CMV-Cre–KO mice were 
born at expected Mendelian ratios and lived to adulthood with no 
observed phenotypic abnormalities.
We detected expression of Gpr182 lacZ by β-gal activity as ear-
ly as E8.0 in dorsal aorta and vitelline veins (Figure 1B and Sup-
plemental Figure 2A), similar to previously published ISH observa-
tions (10). By E13.5, we observed Gpr182 expression in numerous 
organs including heart, lung, liver, aorta, and carotid arteries (Fig-
ure 1C and Supplemental Figure 2, B and C). Expression of Gpr182 
in embryonic heart was detected in both atria and ventricles, par-
ticularly in the ventricular trabecular region (Figure 1D). At E17.5, 
Gpr182 localization remained prominent in the heart, lungs, and 
liver, but was also observed in embryonic kidneys, glandular stom-
ach, intestine, spleen, and yolk sac vasculature (Figure 1E and Sup-
plemental Figure 2D).
In adult mice Gpr182 was widely expressed throughout the 
body. Cardiac expression was localized to the endocardium of the 
atria and ventricles, as well as in the heart valves and coronary arter-
ies (Figure 1F and Supplemental Figure 2E). Notably, we observed 
little to no staining in cardiomyocytes, fibroblasts, epicardium, or 
capillary endothelium. Lungs expressed high levels of Gpr182 pri-
marily in endothelial cells (Figure 1G, Supplemental Figure 1C and 
Supplemental Figure 2F). Though Gpr182 was expressed in renal 
In this study, we aimed to identify novel functions of the 
orphan GPR182 in vivo by first mapping the murine Gpr182 expres-
sion pattern during development and in adulthood, and then next 
elucidating the effects of Gpr182 reduction on intestinal homeo-
stasis, regeneration, and adenoma formation.
Results
Orphan GPR182 is widely expressed throughout development and 
adulthood. The Gpr182tm2a(KOMP)Wtsi/+ mouse (hereafter referred to 
as the Gpr182lacZ/+ mouse) was generated and used to both map 
the murine Gpr182 expression pattern during development and 
adulthood as well as act as a loss-of-function model (29). A gene 
trap cassette bearing an En2 splice acceptor upstream of a lacZ 
reporter was knocked into the murine Gpr182 locus immediately 
downstream of exon 1, resulting in expression of lacZ instead of 
the endogenous protein–coding sequence in exon 2 (Figure 1A). 
When crossed to achieve homozygosity, the Gpr182lacZ/lacZ animals 
had a significant reduction of approximately 85% in endogenous 
Gpr182 expression in jejunum and negligible levels in other tis-
sues compared with Gpr182+/+ mice (Supplemental Figure 1, A 
and B; supplemental material available online with this article; 
doi:10.1172/JCI87588DS1). When crossed with the ubiquitously 
expressed CMV-Cre mouse, the resulting Gpr182Δ/Δ CMV-Cre mice 
had undetectable Gpr182 expression in the jejunum compared 
Figure 2. Gpr182 is enriched in CBC ISCs. (A) Optical projection tomography of X-gal–stained optically cleared duodenum from Gpr182+/+ and Gpr182lacZ/lacZ adult 
mice. (B) Representative whole-mount X-gal–stained small intestine from adult Gpr182lacZ/lacZ mice. (C) Cross-sectional X-gal staining of adult Gpr182lacZ/lacZ 
small intestine crypts counterstained with eosin. Arrows indicate Paneth cells. (D) Immunofluorescence of β-gal (green) and DAPI (purple) of intestine from 
adult Gpr182+/+ and Gpr182lacZ/lacZ mice. (E) Crypt from Gpr182lacZ/lacZ jejunum costained with β-gal (green), the Paneth cell marker Lysozyme (magenta), and 
DAPI (blue). Yellow asterisks mark CBC ISCs as defined by morphologic position, elongated nuclei, and Lysozyme negativity. (F) Relative Gpr182 expression 
in isolated epithelial cell populations from (F) Lgr5-EGFP mice and (G) Sox9-EGFP–Tg mice. Differentiated epithelium (Lgr5- EGFPNegative); early progenitors 
(Lgr5- EGFPLow); CBC ISCs (Lgr5-EGFPHigh or Sox9-EGFPLow); enterocytes/goblet cells (Sox9-EGFPNegative); transit- amplifying cells (Sox9-EGFPSublow); enteroendo-
crine/Tuft/+4 ISCs (Sox9-EGFPHigh); and Paneth cells (Sox9-EGFPNegative CD24High SSCHigh). Expression was normalized to Lgr5-EGFPNegative or Sox9-EGFPNegative cell 
populations and Actb. Biological replicates: n = 2–5 mice per population (F–G). Scale bars: 500 μm (A),  200 μm (B), and 10 μm (C–E). *P < 0.05 and **P < 0.01, 
by 1-way ANOVA with Tukey’s multiple comparisons test.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
5 9 6 jci.org   Volume 127   Number 2   February 2017
Gpr182 X-gal staining was also robust in spermatocytes of the adult 
testis (Supplemental Figure 2I). Spleen and lymph nodes revealed 
endothelial Gpr182 localization, with little to no detectable staining 
in mature or developing hematopoietic and lymphoid lineages (Sup-
plemental Figure 2, J and K). We observed little to no X-gal staining 
in skeletal muscle, pancreas, brain, spinal cord, or dorsal root gan-
glia of adult mice (Supplemental Figure 2, L–O).
Gpr182 is expressed throughout the intestine and is enriched in 
small ISCs. Whole-mount X-gal staining and histology revealed 
an interesting pattern of staining in the crypt epithelial cells of the 
small intestine, with only a few positively stained secretory cells 
in the villi and relatively little staining in enterocytes or submuco-
sal endothelial cells (Figure 2, A and B, and Supplemental Figure 
3). We found that β-gal staining was most intense in the stem cell 
tubules during late gestation (Supplemental Figure 2D), we found 
that adult renal localization was primarily enriched in the glomer-
uli, where it appeared strikingly specific to podocytes (Figure 1H 
and Supplemental Figure 2G). Sinusoidal endothelial cells, rather 
than hepatocytes, were the primary cell type expressing Gpr182 in 
the liver (Figure 1I). We found that Gpr182 was expressed through-
out the fundus and antrum (Figure 1J, Supplemental Figure 2H, 
and Supplemental Figure 3). Interestingly, this Gpr182 localiza-
tion was detected in gastric epithelial cells primarily near the base 
of the glands in both fundus and antrum, although we observed a 
few lacZ+ cells higher up the gland in the fundus. We did not detect 
staining in acid-secreting parietal cells (Figure 1J and Supplemental 
Figure 3, B and C). We detected X-gal staining in the distal colon, 
also at the base of the crypts (Figure 1K and Supplemental Figure 3). 
Figure 3. Reduced Gpr182 does not alter basal proliferation in vivo. (A) Length of small intestines from adult Gpr182+/+, Gpr182lacZ/lacZ, and Gpr182Δ/Δ CMV-
Cre mice. (B) Morphometric quantification of crypt density and (C) histological quantification of crypt depth among Gpr182 genotypes. (D) Representative 
images and (E) EdU incorporation quantification of intestinal proliferation in Gpr182+/+ and Gpr182lacZ/lacZ animals. (F) Analysis of the cellular position of 
EdU+ cells along the crypt axis expressed as a percentage of the total number of cells in that position in all crypts. n = 20–60 open crypts per region per 
mouse. The Gpr182 zone (green gradient) is the relative cellular position of β-gal+ cells along the crypt axis. (G) Relative expression of Ccnd1, Lgr5, Olfm4, 
hairy and enhancer of split 1 (Hes1), chromogranin A (Chga), and Lysozyme (Lyz2) in whole jejunum from Gpr182+/+ CMV-Cre and Gpr182Δ/Δ CMV-Cre mice. 
Expression was normalized to Gpr182+/+ and 18S. Biological replicates: n = 3–5 mice per genotype. Scale bars: 100 μm. Significance was determined by 
either 1-way ANOVA with Tukey’s multiple comparisons test.
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2E), closely resembling the pattern of other markers of the active 
CBC ISCs (19–22). The gastrointestinal lacZ expression pattern of 
Gpr182Δ/+ CMV-Cre and Gpr182Δ/Δ CMV-Cre mice was similar to 
that observed in Gpr182lacZ/+ mice (Supplemental Figure 3).
zone at the base of crypts of Lieberkühn compared with the tran-
sit-amplifying cells residing higher in the crypt/villus axis (Figure 
2, C–E). More specifically, β-gal–stained thin cells with elongated 
nuclei were intercalated between Lysozyme+ Paneth cells (Figure 
Figure 4. Decreased Gpr182 leads to hyperproliferation during the regeneration phase 
after irradiation-induced injury. Adult Gpr182+/+ (purple) and Gpr182lacZ/lacZ (green) mice 
were challenged with a single 14-Gy dose of radiation (IRR) to the abdomen. (A) BW 
changes (percentage of pre-IRR weight) of Gpr182+/+ and Gpr182lacZ/lacZ mice for 5 days 
following IRR compared with BW of non-IRR control mice. Small intestine length (B) and 
regenerating crypt depth (C) in IRR-treated Gpr182+/+ and Gpr182lacZ/lacZ animals. (D) Whole-
mount X-gal–stained small intestine from non-IRR–treated Gpr182lacZ/lacZ and IRR-treated 
Gpr182lacZ/lacZ animals 5 days after IRR. (E) Relative expression of Gpr182 and ISC markers 
Lgr5, Bmi1, and Lrig1 in whole jejunum from Gpr182+/+ IRR, Gpr182lacZ/lacZ IRR, and non-IRR 
Gpr182+/+ animals. Expression was normalized to non-IRR Gpr182+/+, Gapdh, and 18S. (F) 
Representative images and (G) EdU quantification of intestinal proliferation among IRR 
Gpr182+/+ and Gpr182lacZ/lacZ animals. (H) Analysis of the cellular position of EdU+ cells along 
the crypt axis expressed as a percentage of the total number of cells in that position in 
all regenerating crypts. n = 10–60 open crypts per region per mouse. Biological replicates: 
n = 4–5 mice per genotype. Scale bars: 5 mm (D) and 100 μm (F). *P < 0.05, **P < 0.01, 
and ***P < 0.001, by 2-tailed Student’s t test (B, C, and G), 1-way ANOVA with Tukey’s 
multiple comparisons test (E), or Mann-Whitney t test of the AUC (H).
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To further verify the enrichment of Gpr182 in CBC ISCs in 
models without altered Gpr182 expression, the Lgr5-EGFP and 
Sox9-EGFP BAC–Tg mice were used to isolate different intes-
tinal epithelial cell populations with distinct levels of EGFP, as 
previously described (18, 19, 25, 30–32). Gpr182 transcripts were 
significantly enriched in the Lgr5-EGFPHigh CBC ISC popula-
tion compared with transcript expression of the differentiated 
Lgr5-EGFPNegative population, with intermediate expression in the 
Lgr5-EGFPLow progenitors (Figure 2F). Likewise, Gpr182 mRNA 
was enriched in the CBC ISC population (Sox9-EGFPLow) when 
compared with populations containing transit-amplifying cells 
(Sox9-EGFPSublow) and a mixed population of enterocytes and 
goblet cells (Sox9-EGFPNegative) (Figure 2G). Furthermore, Gpr182 
expression was very low in isolated Paneth cells. Consistent with 
the previous observation of rare β-gal+ cells in the villus region, we 
found that Gpr182 also was enriched in the Sox9-EGFPHigh cell pop-
ulation, which is a mixed population of enteroendocrine cells, tuft 
cells, and activatable reserve ISCs (18, 31, 32). While Gpr182 is not 
exclusively expressed in CBC ISCs, like Lgr5, these data provide 
evidence that Gpr182 is enriched in CBC ISCs at the crypt base, as 
well as in the Sox9-EGFPHigh cell population that contains activat-
able reserve ISCs.
Gpr182 reduction does not alter intestinal proliferation during 
homeostasis in vivo. To evaluate the potential roles of GPR182 in 
ISCs, we first characterized intestinal proliferation during homeo-
stasis in Gpr182lacZ/lacZ mice and, consistent with the highly regu-
lated nature of the ISC niche, we found no significant effects of 
Gpr182 reduction on homeostatic intestinal proliferation. For 
example, small intestine and colon lengths were unchanged in 
the Gpr182lacZ/lacZ animals compared with that observed in controls 
(Figure 3A and Supplemental Figure 4A). Intestinal crypt density, 
as a proxy for crypt fission, was unaltered between the genotypes 
(Figure 3B). Crypt depth was also unchanged, consistent with no 
significant differences in basal proliferation, as evidenced by sim-
ilar numbers of EdU+ cells per crypt, across the genotypes in both 
the small intestine and colon (Figure 3, C–E, and Supplemental 
Figure 4, B–D). Likewise, there was no difference in the number of 
phosphorylated histone H3+ (p–histone H3+) cells per crypt in the 
small intestine (Gpr182+/+: 1.26 ± 0.13 cells/crypt and Gpr182lacZ/lacZ: 
1.33 ± 0.10 cells/crypt, n = 5). The β-gal+ cells were primarily locat-
ed in the lowest 4 cell positions of the crypt, and there were no 
significant changes in the position of proliferating transit-ampli-
fying zone cells between the genotypes (Figure 3F). Additionally, 
expression levels of cyclin D1 (Ccnd1) and Lgr5 were unchanged 
in the Gpr182Δ/Δ CMV-Cre mouse jejunum compared with levels 
detected in Gpr182+/+ CMV-Cre controls (Figure 3G). Expression 
of the Notch targets Olfm4 and Hes1 as well as the differentiation 
markers Chga and Lysozyme were not significantly altered in these 
mice. Collectively, these data demonstrate that genetic reduction 
of Gpr182 does not lead to altered intestinal proliferation in vivo, 
which is consistent with the highly regulated control of intestinal 
proliferation during homeostasis.
Mice with Gpr182 knockdown show intestinal hyperproliferation 
during intestinal regeneration following irradiation injury. To test 
whether GPR182 may be involved with regulating proliferation 
during intestinal regeneration following damage, Gpr182+/+ and 
Gpr182lacZ/lacZ mice were exposed to a high dose (14 Gy) of ioniz-
ing radiation delivered to the abdomen. It is well established that 
intestinal irradiation (IRR) causes apoptosis of actively dividing 
cells, leading to the temporary loss of proliferative crypts and villi, 
with subsequent surviving ISCs expanding and regenerating the 
damaged intestinal epithelium and peak proliferation occurring 
5 days after IRR (18, 32–35). Both Gpr182+/+ and Gpr182lacZ/lacZ IRR 
animals lost approximately 20% of their initial BW 5 days after IRR 
compared with the non-IRR controls (Figure 4A). Interestingly, 
the small intestine and colon were significantly longer in the Gpr-
182lacZ/lacZ IRR mice compared with controls (Figure 4B and Supple-
mental Figure 4A). During regeneration, Gpr182lacZ/lacZ IRR mouse 
small intestines had significantly increased crypt depth compared 
with that seen in IRR control mice (Figure 4C). While X-gal stain-
ing was observed in crypts throughout the small intestine in non-
IRR Gpr182lacZ/lacZ mice (Figure 4D and Supplemental Figure 3A), 
the vast majority of regenerative crypts in the Gpr182lacZ/lacZ IRR 
mice were X-gal negative (Figure 4D). Gpr182 expression in whole 
jejunum was decreased at this phase of regeneration in Gpr182+/+ 
mice compared with expression in non-IRR controls (Figure 4E). 
Likewise, expression of the CBC ISC marker Lgr5 was decreased 
in IRR tissue, but unchanged between genotypes. Expression 
of the activatable ISC markers Bmi1 and Lrig1 was unchanged 
between the genotypes, although expression trended lower in the 
Gpr182lacZ/lacZ IRR mouse jejunum.
There were significantly more EdU+ cells per crypt in the 
regenerating duodenum and jejunum of Gpr182lacZ/lacZ IRR mice 
compared with Gpr182+/+ IRR controls, with comparable, but not 
statistically significant, trends in the ileum and colon (Figure 4, F 
and G, and Supplemental Figure 4, C and D). The percentage of 
EdU+ cells was increased in the bottom third of the regenerating 
crypt (Figure 4H). The number of p–histone H3+ cells per crypt was 
also significantly increased in the regenerating Gpr182lacZ/lacZ duo-
denum (Gpr182+/+: 2.51 ± 0.39 cells/crypt and Gpr182lacZ/lacZ: 3.74 ± 
0.18 cells/crypt, n = 4–5; *P  <0.05). Together, these data indicate 
a role for GPR182 in limiting proliferation during intestinal epithe-
lial regeneration.
Mice with reduced Gpr182 that carry the ApcMin/+ allele have 
increased intestinal adenoma burden and decreased survival. Since 
Gpr182 acts to inhibit proliferation during regeneration, we rea-
soned that Gpr182 levels may also be important in deregulated 
proliferation during disease, such as intestinal adenoma and car-
cinoma. Gpr182lacZ/lacZ adults up to 2 years of age did not develop 
spontaneous intestinal adenomas (n = 6; data not shown). Thus, 
to investigate whether Gpr182 is involved in intestinal adenoma 
initiation and progression, Gpr182lacZ/lacZ mice were crossed with 
the well-characterized ApcMin mouse model, which develops 
spontaneous intestinal and colonic adenomas caused by aber-
rant activation of the Wnt/β-catenin signaling pathway (36, 37). 
Both male and female 5-month-old Gpr182lacZ/+ ApcMin/+ and Gpr-
182lacZ/lacZ  ApcMin/+ mice were characterized for adenoma forma-
tion and compared with Gpr182+/+ ApcMin/+ controls. The major-
ity of Gpr182+/+ ApcMin/+ (71 of 76) and Gpr182lacZ/+ ApcMin/+ (37 of 
39) animals survived past 5 months of age (Figure 5A). Howev-
er, significantly fewer Gpr182lacZ/lacZ ApcMin/+ (62 of 96) mice sur-
vived past 5 months, indicating that genetic reduction of Gpr182 
exacerbates the lethality of C57BL/6-ApcMin/+ mice. Furthermore, 
both Gpr182lacZ/lacZ ApcMin/+ male and female mice had significant-
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ly lower BW at 5 months compared with the BW of sex-matched 
controls (Figure 5B). The spleens from both Gpr182lacZ/+ and Gpr-
182lacZ/lacZ animals weighed significantly more when compared 
with spleen weights of controls (Figure 5C). The small intestines 
were also significantly longer in the Gpr182lacZ/lacZ ApcMin/+ animals 
compared with control small intestine lengths (Figure 5D), which 
was similar to the response in mice treated with IRR (Figure 4C). 
Together, these data suggest that attenuated Gpr182 expression 
Figure 5. Reduced Gpr182 increases lethality and polyp numbers in ApcMin/+ mice. (A) Kaplan-Meier survival curve comparing Gpr182lacZ/lacZ Apc+/+ (black), 
Gpr182+/+ ApcMin/+ (blue), Gpr182lacZ/+ ApcMin/+ (yellow), and Gpr182lacZ/lacZ ApcMin/+ (red) animals. (B) BW of 5-month-old female and male ApcMin mice from different 
Gpr182 genotypes. (C) Spleen weight normalized to BW for Gpr182+/+ ApcMin/+, Gpr182lacZ/+ ApcMin/+, and Gpr182lacZ/lacZ ApcMin/+ mice. (D) Small intestine length from 
Gpr182lacZ/lacZ ApcMin/+ animals compared with controls. (E) Representative images of the number and size of adenomas from Gpr182+/+ ApcMin/+ and Gpr182lacZ/lacZ 
ApcMin/+ mouse intestines. (F) Quantification of polyp numbers throughout the small intestines of Gpr182+/+ ApcMin/+, Gpr182lacZ/+ ApcMin/+, and Gpr182lacZ/lacZ ApcMin/+ 
mice. (G) Distribution of the number of polyps throughout the small intestine based on approximate polyp size. (H) Histology for 5-month-old Gpr182+/+ ApcMin/+ 
and Gpr182lacZ/lacZ ApcMin/+ jejunum polyps labeled with H&E and β-catenin (white). (I and J) Polyp proliferation assessed by Ki67 (blue) staining normalized to 
DAPI (purple) in Gpr182+/+ ApcMin/+ and Gpr182lacZ/lacZ ApcMin/+ mice. (K) Gpr182 expression in polyps from jejunum of Gpr182+/+ ApcMin/+ and Gpr182lacZ/lacZ ApcMin/+ mice 
compared with expression levels in Apc+/+ jejunum. Expression was normalized to Gpr182+/+, Gapdh, and 18S. Scale bars: 5 mm (E) and 100 μm (H and I). Biologi-
cal replicates: n = 25–100 mice per genotype (A); n = 10–20 mice per genotype per sex (B); n = 700–1,700 polyps from 20 to 35 mice per genotype (C, D, F, and G);  
n = 15–60 polyps from 5 mice (J); and n = 3–5 mice per genotype (K). *P < 0.05, **P < 0.01, and ***P < 0.001, by Mantel-Cox test (A), 1-way ANOVA Kruskal-Wallis 
test with Dunn’s multiple comparisons test (B–G), Mann-Whitney t test (J), or 1-way ANOVA with Tukey’s multiple comparisons test (K).
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tions between the Gpr182+/+ and Gpr182lacZ/lacZ animals 
(Figure 5, I and J), although polyp proliferation in the 
Gpr182lacZlacZ ApcMin/+ mice appeared more heteroge-
neous. Gpr182 expression was significantly decreased in 
ApcMin/+ polyps compared with normal WT jejunum (Fig-
ure 5K). Consistent with the highly mosaic nature of 
adenomas (38, 39), macroscopic and histologic analysis 
of Gpr182-associated X-gal and β-gal antibody staining 
revealed a mosaic staining pattern between polyps and 
within individual polyps (Supplemental Figure 5). We 
consistently observed X-gal staining in microadeno-
mas (Supplemental Figure 5C), and polyp Ki67-labeled 
proliferation appeared inversely correlated with Gpr182 
β-gal staining, supporting the notion of heterogeneous 
Gpr182 promoter activity (Supplemental Figure 5, D 
and E). Together, these data support the idea that GPR182 plays 
a role in preventing adenoma formation, but it does not appear to 
directly alter adenoma progression.
Loss of Gpr182 increased single-cell organoid growth efficiency. 
Considering the proliferative phenotypes observed during regen-
eration and adenoma formation in Gpr182lacZ/lacZ animals, we 
sought to determine whether the loss of Gpr182 altered intestinal 
stem cell numbers and/or proliferative capacity. We isolated single 
crypt epithelial cells from Gpr182+/+ CMV-Cre and Gpr182Δ/Δ CMV-
Cre jejunum using FACS to select CD326+CD44+ cells, as previous-
ly reported (40, 41). Neither the percentage of CD326+ epithelial 
cells nor the proportion of CD44– and CD44+ epithelial cells was 
altered with the loss of Gpr182 (Supplemental Figure 6, A and B). 
We observed no significant differences in the expression of either 
active (Lgr5 and Olfm4) or reserve (Bmi1, Tert, Lrig1) ISC markers 
in the CD326+CD44+ cell population from Gpr182+/+ and Gpr182Δ/Δ 
mice (Figure 6A). Single CD326+CD44+ and CD326+CD44– cells 
were seeded in Matrigel and cultured in supplemented media for 
7 days to assay ISC numbers, survival, and proliferative capacity, 
as previously reported (40–42). As expected, CD326+CD44– cells 
formed very few colonies that were viable after 7 days, with no 
significant difference observed between Gpr182+/+ and Gpr182Δ/Δ 
mice (Supplemental Figure 6, C–E). Initially the efficiency of 
CD326+CD44+ cells in forming organoids was similar between 
Gpr182+/+ and Gpr182Δ/Δ mice (Figure 6B), suggesting a relatively 
equal distribution of ISCs and/or progenitors between the gen-
otypes. However, after 5 days and 7 days in culture, when only 
organoids initiated and maintained by self-renewing ISCs are 
present, Gpr182Δ/Δ mice had significantly more viable and larg-
is detrimental to the health and survival of ApcMin/+ animals. For 
both sexes, macroscopic polyp numbers throughout the intestine 
were 3- to 4-fold higher in Gpr182lacZ/lacZ ApcMin/+ mice compared 
with polyp numbers in Gpr182+/+ ApcMin/+ controls (Figure 5, E and 
F). Moreover, the haploinsufficient Gpr182lacZ/+ ApcMin/+ mice also 
showed significantly more polyps in the small intestine than did 
Gpr182+/+ ApcMin/+ controls, further supporting the idea of a genet-
ic dose-dependent inverse correlation between Gpr182 levels and 
polyp formation. There were significantly more polyps of all siz-
es in the Gpr182lacZ/lacZ ApcMin/+ mice than in the Gpr182+/+ ApcMin/+ 
mice, but the relative distribution of small and large polyps was 
unchanged between these genotypes (Figure 5G).
The ApcMin/+ model shows fewer and more sporadic polyps in 
the colon after 5 months. Consistently, colon polyps occurred in 
66% of the Gpr182+/+ ApcMin/+ mice assessed, while the incidence of 
colon polyps was 84% in the Gpr182lacZ/lacZ ApcMin/+ mice. Moreover, 
we observed a 2-fold increase in the number of colon polyps in the 
Gpr182lacZ/lacZ ApcMin/+ animals compared with colon polyp num-
bers in the Gpr182+/+ ApcMin/+ controls (2.0 ± 0.3 versus 1.0 ± 0.2 
polyps, respectively; *P < 0.05). Together, these data indicate that 
decreased Gpr182 expression is sufficient to exacerbate ApcMin/+ 
adenoma formation and burden throughout the intestine, further 
supporting the idea that Gpr182 has a role in negatively regulating 
intestinal proliferative capacity.
While adenoma formation was increased in the Gpr182lacZlacZ 
ApcMin/+ animals, no morphological differences were observed in 
Gpr182lacZ/lacZ polyps compared with Gpr182+/+ polyps (Figure 5H). 
Furthermore, there were no qualitative or quantitative differ-
ences in overall proliferation within individual polyp cross-sec-
Figure 6. Loss of Gpr182 leads to increased growth efficiency of 
single-crypt epithelial cells ex vivo. (A) Relative expression of 
ISC markers in isolated CD326+CD44+ cells from Gpr182+/+ CMV-
Cre and Gpr182Δ/Δ CMV-Cre jejunum. Expression was normalized 
to Gpr182+/+ CMV-Cre, Actb, and 18S. (B) Growth efficiency of 
single CD326+CD44+ cells isolated from Gpr182+/+ CMV-Cre and 
Gpr182Δ/Δ CMV-Cre jejunum and cultured for 7 days ex vivo. One 
thousand CD326+CD44+ cells were initially plated in triplicate per 
mouse. (C) Area quantification of CD44+ colonies after 7 days in 
culture. (D) Representative images of organoid density and size 
after 7 days in culture. Scale bars: 500 μm. Biological replicates: 
n = 3 mice. Significance was determined by 2-tailed Student’s  
t test (A and B) or Mann-Whitney t test (C).
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Decreased GPR182 is correlated with aberrant ERK1/2 activa-
tion during homeostasis, regeneration, and in ApcMin/+ mice. Class A 
GPCRs commonly activate or inhibit the MAPK signaling cascade, 
which has numerous downstream effects on cell proliferation 
and survival, but the signal transduction pathways of the orphan 
GPR182 have not been characterized. ERK1/2 signaling was local-
ized in both epithelial and nonepithelial cells in the small intestine. 
er organoids than did Gpr182+/+ mice (Figure 6, B–D). A number 
of these Gpr182Δ/Δ organoids were X-gal+ and had an increased 
number of p–histone H3+ cells (Supplemental Figure 6, E and F). 
These data demonstrate that isolated ISCs from these animals 
have increased survival and proliferative potential ex vivo and fur-
ther the conclusion that GPR182 acts to regulate the proliferative 
capacity of ISCs in the small intestine.
Figure 7. Reduced Gpr182 leads to elevated ERK1/2 signaling upstream of the hyperproliferative intestinal crypt microenvironment. (A) Immunofluo-
rescence of p-ERK1/2 (red) staining in Gpr182+/+ and Gpr182lacZ/lacZ intestine during homeostasis, 5 days after IRR, and in ApcMin/+ animals. Yellow asterisks 
mark crypts. (B) Colocalization of β-gal+ (green) ISCs with p-ERK1/2 in Gpr182lacZ/lacZ compared with Gpr182+/+ crypts. Scale bars: 50 μm (A) and 20 μm (B). 
(C) Representative immunoblots and quantification of relative p-ERK1/2 expression in unchallenged, 5 days post-IRR, and ApcMin/+ polyps from whole 
jejunum lysates derived from Gpr182+/+ and Gpr182lacZ/lacZ mice. Samples were normalized to total ERK1/2 and Gpr182+/+. GAPDH was used as a loading 
control. Biological replicates: n = 5–10 mice per genotype per condition. *P < 0.05 and **P < 0.01, by unpaired t test. (B) Model summarizing GPR182 β-gal 
expression pattern (blue) in the whole mouse (heart, lungs, liver, stomach, small intestine, colon, kidney, and testis), with more specific expressional detail 
within the small intestine. GPR182 functions to inhibit ERK1/2 signaling to regulate the proliferative capacity of the intestine.
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that GPR182 expression was significantly lower in colon ade-
nocarcinoma when compared with expression levels in patient-
matched normal colon tissue (Figure 8) and nonmatched sam-
ples (normal colon: 0.86 ± 0.17, n = 41; colon adenocarcinoma: 
0.24 ± 0.04, n = 285; ***P < 0.0001, by Mann-Whitney t test). 
GPR182 expression was also significantly downregulated in 
numerous carcinomas in tissues other than the colon, including 
bladder, breast, bile duct, kidney, liver, lung, pancreas, thyroid, 
and uterine carcinomas (Figure 8). While loss of GPR182 may 
not drive carcinoma initiation in mice, these data further sup-
port the idea that low GPR182 expression is inversely correlated 
with increased proliferative capacity in mice and humans.
Discussion
We generated and used a genetic Gpr182-lacZ–knockin mouse 
model to gain insights into the tissue localization and physiological 
functions of GPR182. Although it is possible that genetic reduction 
of Gpr182 expression may influence its lacZ reporter localization, 
our characterization using the lacZ reporter is entirely consistent 
with previously published ISH and microarray data (9, 10), as well 
as expression analysis from GPR182-independent models, includ-
ing Lgr5-EGFP and Sox9-EGFP mice. The intestinal expression 
pattern — particularly the crypt localization — piqued our interest 
and became the focus of this study. However, it is worth emphasiz-
ing that Gpr182 is expressed in a variety of tissues and cell types, 
particularly in the endothelium, which will certainly prompt addi-
tional physiological studies. Furthermore, these types of physi-
ological in vivo studies may prove instructive with regard to the 
eventual “deorphanization,” or identification, of endogenous 
ligand(s) of GPR182, which currently remains unknown.
Our study shows that Gpr182 is expressed in the epithelium 
throughout the gastrointestinal tract and is particularly enriched 
in the CBC ISCs of the small intestine. Like LGR5, GPR182 is a 
GPCR enriched in ISCs but appears to be a less selective ISC mark-
er. The genetic reduction of Gpr182 did not alter intestinal mor-
phology or proliferation during homeostasis in vivo, which is con-
sistent with the tightly regulated control of epithelial proliferation 
During homeostasis, epithelial p-ERK1/2 appeared highest in the 
transit-amplifying zone and right above the crypt, with relatively 
little activity in the crypt base ISCs (Figure 7, A and B) (43). How-
ever, during regeneration and in ApcMin/+ animals, p-ERK1/2 was 
much higher throughout the epithelium, especially at the base of 
crypts (Figure 7A). Mosaic p-ERK1/2 was also observed within 
adenomas from ApcMin/+ animals (Supplemental Figure 5F). We 
observed occasional β-gal+ p-ERK1/2+ ISCs in Gpr182lacZ/lacZ mice 
during homeostasis (Figure 7B). Significantly increased p-ERK1/2 
was observed in Gpr182lacZ/lacZ jejunum compared with Gpr182+/+ 
controls, and this increase was observed during homeostasis, 
regeneration, and in ApcMin/+ polyps (Figure 7C). Interestingly, the 
increased organoid growth efficiency in Gpr182Δ/Δ CD326+CD44+ 
single cells was dependent on the addition of exogenous EGF (Sup-
plemental Figure 7, A–C). The expression of Egfr was not altered 
in Gpr182Δ/Δ or Gpr182lacZ/lacZ IRR jejunum compared with expres-
sion in controls (Supplemental Figure 7D). These data suggest that 
EGF-mediated MAPK signaling is still required for the increased 
proliferative capacity of these Gpr182-null organoids.
Unlike ERK1/2 signaling, the phosphorylation of other signal-
ing kinases, including p38 MAPK, AKT, STAT3, and YAP, appeared 
relatively unaltered in whole jejunum in Gpr182+/+ and Gpr182lacZ/lacZ 
mice (Supplemental Figure 8). Therefore, the correlation between 
decreased Gpr182 and increased ERK1/2 signaling, along with the 
crypt and ISC localization of p-ERK1/2, especially during regen-
eration and in ApcMin/+ mice, suggests that GPR182 regulation of 
ERK1/2 occurs upstream of the increased proliferative capacity we 
observed in the Gpr182lacZ/lacZ mice (Figure 7D).
GPR182 expression is reduced in numerous human carcino-
mas, including colon adenocarcinomas. Considering that reduced 
Gpr182 increased the intestinal proliferative capacity in mice, 
we sought to determine whether GPR182 expression levels are 
changed in human carcinomas. First, we found that GPR182 
expression was low in numerous human colorectal carcinoma 
cell lines, including CaCo2, HT29, Colo205, and SW480 (Sup-
plemental Figure 9). Second, RNA-sequencing (RNA-seq) data 
from The Cancer Genome Atlas (TCGA) (44, 45) confirmed 
Figure 8. Low GPR182 expression in human carcinomas. Relative GPR182 expression determined by TCGA RNA-seq of patient-matched normal (N) 
and tumor (T) tissue. Bladder urothelial carcinoma (BLCA), n = 19; breast invasive carcinoma (BRCA), n = 98; cholangiocarcinoma (CHOL), n = 9; colon 
adenocarcinoma (COAD), n = 26; kidney chromophobe (KICH), n = 25; kidney renal clear cell carcinoma (KIRC), n = 71; kidney renal papillary cell carcinoma 
(KIRP), n = 32; liver hepatocellular carcinoma (LIHC), n = 50; lung adenocarcinoma (LUAD), n = 57; lung squamous cell carcinoma (LUSC), n = 50; pancre-
atic adenocarcinoma (PAAD), n = 58; rectum adenocarcinoma (READ), n = 6; stomach adenocarcinoma (STAD), n = 32; thyroid carcinoma (THCA), n = 57; 
uterine corpus endometrial carcinoma (UCEC), n = 7. *P < 0.05, **P < 0.01, and ***P < 0.001, by Wilcoxon matched-pairs, 2-tailed t test.
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and adenoma formation. Future studies to identify the ligand for 
this exciting and physiologically relevant orphan GPCR will shed 
light on its tractability as a potential therapeutic target.
Methods
Experimental animals. The Gpr182tm2a(KOMP)Wtsi/+ (knockout first/promot-
er driven) mice used in this study were created from an embryonic 
stem (ES) cell clone (EPD0365_4_C08) obtained from the National 
Center for Research Resources–NIH–supported Knockout Mouse 
Project (KOMP) repository and generated by the CHORI, Sanger 
Institute, and UC Davis (CSD) Consortium for the NIH-funded KOMP 
(29). The CSD-targeted allele has been previously published (62, 63). 
To achieve ubiquitous deletion, Gpr182tm2a(KOMP)Wtsi/+ mice were crossed 
with the B6.C-Tg(CMV-cre)1Cgn/J Tg mouse line (The Jackson Labora-
tory; stock no. 006054). For adenoma studies, Gpr182lacZ/+ mice were 
crossed with the C57BL/6J-ApcMin/+/J mouse line (The Jackson Labo-
ratory; stock no. 002020). All Gpr182-associated mouse lines were 
maintained on an isogenic C57BL/6 background. Previously pub-
lished Sox9-EGFP BAC–Tg mice on a CD-1 background and C57BL/6 
Lgr5-EGFP mice (The Jackson Laboratory; stock no. 008875) were 
used for cell isolation and expression verification (18, 19, 25, 30–32). 
The genotyping primers used are listed in Supplemental Table 1.
Animal procedures and dissection. For irradiation challenge, 10- to 
14-week-old female Gpr182+/+ and Gpr182lacZ/lacZ mice were subjected 
to abdominal ionizing radiation as previously described (18). Briefly, 
under isoflurane anesthesia, mice received 14 Gy radiation (50 cm, 
F1 Filter; X-Rad 320; Precision X-Ray) to their abdomens. Experi-
mental and control mice were irradiated at the same time to ensure 
equivalent radiation dosages and rates (~2.8 Gy/min for 300 s). 
Mice were observed and weighed daily to monitor the severity of 
irradiation and overall health. Five days after irradiation, mice were 
injected i.p. with 4 μg 5-ethynyl-2′-deoxyuridine (EdU) per 1 g BW. 
After 90 minutes, mice were euthanized, and gastrointestinal tissue 
was collected for histology and biochemistry. For adenoma studies, 
male and female mice were monitored for health (physical appear-
ance, BW, bloody stool) and euthanized for tissue collection at 5 
months of age. The small intestines and colons were removed and 
flushed with cold PBS. The entire intestinal length was measured and 
then separated into duodenum, jejunum and ileum. The small intes-
tines and colons from all ApcMin/+ mice were opened along the entire 
length, flattened, and macroscopic polyp numbers and sizes were 
quantified. Tissues were then processed for histology, whole-mount 
X-gal staining, and biochemistry. For cryogenic sections, tissue was 
fixed in 4% paraformaldehyde, cryoprotected in 30% sucrose, and 
embedded in OCT before cryosectioning. For histology, tissues were 
fixed in either 4% paraformaldehyde or 10% zinc formalin and then 
paraffin embedded and sectioned.
Single-cell isolation and ex vivo culture. Single cells from jejunum of 
8-week-old female Gpr182+/+ CMV-Cre and Gpr182Δ/Δ CMV-Cre mice 
were isolated and cultured as previously described (31, 32, 40–42, 
64). Briefly, jejuna were flushed and incubated in 3 mM EDTA (Corn-
ing) and 10 μM Y27632 (Selleck Chemicals) in Dulbecco’s PBS. Villi 
were gently scraped with a pipette tip, and the epithelium was sepa-
rated from the submucosa by shaking. The epithelial crypts were fur-
ther dissociated into single cells in 0.3 U/ml dispase (Thermo Fisher 
Scientific), 10 μg/ml DNase (Thermo Fisher Scientific), and Y27632 
in HBSS. Single cells were stained with APC/Cy7-conjugated anti-
for maintaining intestinal health. However, under conditions of 
stress-induced proliferation, such as regeneration following inju-
ry, ApcMin mutation, or ex vivo culture in elevated Wnt signaling 
growth conditions, the reduction of Gpr182 caused hyperprolif-
erative phenotypes, which were associated with elevated ERK1/2 
signaling. Thus, we conclude that GPR182 normally functions to 
directly or indirectly inhibit MAPK-induced intestinal prolifer-
ation (Figure 7D). This inhibitory function is consistent with the 
finding that GPR182 expression is significantly reduced in human 
colon adenocarcinoma — a novel finding that expands the growing 
cadre of negative regulators of proliferation, including LRIG1, that 
have been shown to be downregulated during colorectal tumori-
genesis (20, 46–49). Conversely, numerous pro-proliferative ISC 
markers, such as LGR5, BMI1, and SOX9, have all been shown to 
be upregulated in human colorectal carcinomas (50).
MAPK signaling plays a critical role during regeneration and 
tumorigenesis, which is evidenced by the increased p-ERK1/2 
localization within the crypt and ISCs during these conditions. 
Intestinal epithelial conditional deletion of ERK1/2 leads to rapid 
malabsorption and lethality (43). ERK1/2 activation through sur-
face receptors, such as TLR and/or EGFR, is required for adeno-
ma formation in ApcMin/+ mice, which can be blocked by MEK/ERK 
inhibitors (51, 52). In addition, loss of the RTK negative regulator 
Lrig1 leads to constitutively active EGFR and other ERbB recep-
tors, which lead to increased ERK1/2 signaling, hyperprolifera-
tion, and tumorigenesis (20, 53). Oncogenic mutations in KRAS 
activate numerous downstream kinases, including ERK1/2, which 
rarely initiate tumorigenesis alone but, when combined with Apc 
inactivation, lead to increased adenoma formation and progres-
sion (48, 54–58). GPCRs can activate ERK1/2 directly through 
both G protein– and β-arrestin–mediated signaling, as well as 
indirectly through modulation of EGF/EGFR expression and/
or EGFR transactivation (59, 60). An activating mutation in Gsα 
(GNAS R201C) leads to increased cAMP and ERK1/2 activation, 
which increases adenoma formation when crossed with ApcMin/+ 
mice (61) to an extent similar to that observed in the Gpr182lacZ/lacZ 
ApcMin/+ mice. Alternatively, the trending decrease in Lrig1 expres-
sion in CD326+CD44+ cells and in Gpr182lacZ/lacZ IRR mice supports 
the notion that ErbB signaling may be enhanced in these mice 
and contributes to the hyperproliferative phenotypes. Addition-
ally, organoids arising from single ISCs were dependent on the 
addition of exogenous EGF for the enhanced growth and survival 
observed in Gpr182Δ/Δ ISCs. Thus, it remains possible that GPR182 
could directly inhibit ERK1/2 through the reduction of cAMP lev-
els and/or indirectly through the negative regulation of the EGFR 
signaling pathway. Alternatively, considering that the closest 
paralog to GPR182 is ACKR3, a member of the “decoy” atypical 
chemokine receptor subfamily, it is possible that the effects of 
GPR182 are manifested by its function as a nonsignaling ligand 
sink or “decoy” receptor. Unfortunately, until a ligand (or ligands) 
is identified, it is challenging and premature to try to delineate the 
precise signal transduction pathways that are directly associated 
with GPR182 activity in different cell types.
To our knowledge, this is the first study to use a genetic mouse 
model to simultaneously map Gpr182 localization patterns and 
elucidate novel physiological functions for the negative regulation 
of intestinal proliferative capacity, especially during regeneration 
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4000R CCD color camera with Volocity software (Improvision). Flu-
orescence IHC images were acquired on a Nikon E800 fluorescence 
microscope with a Hamamatsu Orca CCD camera and MetaMorph 
software (Molecular Devices) or a Zeiss LSM 700 confocal micro-
scope. Organoids were imaged on an Olympus IX81 fluorescence 
microscope with a Hamamatsu Orca camera and MetaMorph Basic 
software. Fluorescent images were pseudo-colored using ImageJ soft-
ware (NIH). Image processing, including cropping, brightness, and 
contrast adjustments, were altered equally across comparable images 
using ImageJ and Photoshop CS4 (Adobe).
Morphometry and proliferation quantitation. Crypt depth was quan-
tified by measuring the distance from the bottom of nuclei at the base 
to the top of the crypt from 5 to 30 open crypts from each region of the 
intestine from 5 mice per genotype per treatment. Crypt density was 
assessed by whole-mount microscopy. Three fields per intestinal area 
per genotype were imaged, and crypt the area from 10 crypts per field 
was measured with ImageJ. The approximate number of crypts that 
would fit into a 1-mm2 area was calculated. Proliferation was assayed by 
EdU incorporation and the Click-iT Detection Kit (Thermo Fisher Scien-
tific) and analyzed by counting the number of EdU+ cells per open crypt 
normalized to the total number of DAPI+ crypt cells and expressed as a 
percentage. Cell positions of EdU+ cells along the crypt/villus axis were 
recorded during quantification. Ten to sixty whole, open crypts were 
included from each area of the intestine (duodenum, jejunum, ileum, 
and distal colon) from 5 mice per genotype per treatment. Polyps were 
counted and dimensions were approximated from all polyps measuring 
1 × 1 mm2 or larger throughout the small intestine in all experimental 
mice, and the polyp area was calculated assuming an elliptical shape. A 
total of 700 to 1,700 polyps were counted from 20 to 35 mice per gen-
otype. Proliferation of individual polyps was determined by threshold 
quantification of Ki67+ signal as a ratio of DAPI+ signal in cross-sections 
using ImageJ software. Viable organoids with defined cell borders were 
counted on days 1, 2, 3, 5, and 7 when they were imaged. Researchers 
were blinded to the mouse genotype and treatment.
Real-time PCR analysis. Tissues were either snap-frozen in liquid 
nitrogen or stored in RNAlater (Ambion, Thermo Fisher Scientific). 
Enriched cell populations labeled with CD326 and CD44 or differen-
tial Sox9-EGFP or Lgr5-EGFP levels as previously described (18, 30, 
40–42) were isolated by FACS and collected into RNAqueous- Micro 
Lysis Solution (Ambion, Thermo Fisher Scientific). Likewise, the 
Paneth cell–enriched population was isolated using a previously pub-
lished protocol (31). Human colorectal carcinoma cell lines (ATCC), 
HUVECs (Lonza), and human intestinal epithelial cells, provided by 
J.F. Beaulieu (University of Sherbrooke, Quebec, Canada), were cul-
tured and collected as previously reported (66). RNA was extracted 
using either TRIzol Reagent (Invitrogen, Thermo Fisher Scientific) 
and a Percellys bead homogenizer or RNAqueous-Micro Kit (Ambion, 
Thermo Fisher Scientific) according to standard procedures and then 
subsequently treated with DNase1 (RQ1; Promega) and reverse tran-
scribed with M-MLV (Invitrogen, Thermo Fisher Scientific) or iScript 
(Bio-Rad Laboratories). Quantitative gene expression was assayed 
with 2× TaqMan Master Mix (Applied Biosystems or Bio Basic Inc.) 
and run on a StepOne Plus Real-Time PCR System (Applied Biosyste-
ms, Thermo Fisher Scientific). Primers and probes for real-time PCR 
(RT-PCR) are listed in Supplemental Table 1. Relative expression lev-
els were determined by the ΔΔCt method and normalized to reference 
gene expression of Gapdh, Actb, or 18S.
CD326 (1:100; catalog 118218); Brilliant Violet 421–conjugated anti-
CD44 (1:100; catalog 338810); and 7-AAD (catalog 420404) (all from 
BioLegend). FACS was conducted on an SH800Z Cell Sorter (Sony). 
Debris, doublets, and dead cells were excluded by size and 7-AAD. 
Viable CD326+CD44– and CD326+CD44+ cells (1,000 cells/well) were 
collected into Matrigel. Culture media (31) were supplemented every 
2 days (unless otherwise noted) with 50 ng/ml EGF (Invitrogen, Ther-
mo Fisher Scientific); 100 ng/ml Noggin (Peprotech); 100 nM valproic 
acid (Sigma-Aldrich); 3 μM CHIR99021 (Selleck Chemicals); and 25% 
conditioned R-spondin 2 media.
Whole-mount X-gal staining. Whole-mount X-gal staining was 
adapted from previously published protocols (19). Briefly, whole 
tissue was fixed in 0.2% glutaraldehyde (Electron Microscopy Sci-
ences) for 24 hours at 4°C. Tissue was washed and permeabilized 
with 0.1% triton and incubated in 1 mg/ml X-gal staining buffer 
(Bioline) for approximately 24 hours at room temperature in the 
dark. Tissue was washed and post-fixed in 4% paraformaldehyde 
for 24 hours at 4°C. Samples were washed, imaged, and paraffin 
embedded, and sections were counterstained with 1% Neutral Red 
solution (Sigma-Aldrich) or eosin.
Optical projection tomography. Whole-mount X-gal–stained tis-
sues were embedded in 1% agarose (catalog 105128; Thermo Fisher 
Scientific), dehydrated overnight in absolute methanol, and cleared 
in benzyl alcohol/benzyl benzoate (1:2) as previously described (65). 
Optically cleared specimens were mounted onto aluminum chucks 
and scanned with a 3001m Optical Projection Tomography Scanner 
(BiOPTonics) under bright-field illumination.
IHC. Paraffin and cryogenic sections were rehydrated, permea-
bilized, and blocked with 5% normal donkey serum. When required, 
slides were boiled in citrate buffer for antigen retrieval. Slides were 
then stained overnight at room temperature with the following pri-
mary antibodies: chicken anti–β-gal (1:1,500; catalog BGL-1040; Aves 
Labs Inc.); rabbit anti-lysozyme (1:1,000; catalog PA0391; Leica Bio-
systems); rabbit anti–p-histone H3 (1:500; catalog 9701; Cell Signal-
ing Technology); rat anti-Ki67 (1:30; M7249; DakoCytomation); rab-
bit anti–p-ERK1/2 (1:300; catalog 4370; Cell Signaling Technology); 
rabbit anti–β-catenin (1:500; catalog ab16051; Abcam); rabbit anti-
DCLK1 (1:1,000; catalog ab31704; Abcam); rat anti-CD31 (1:100; cat-
alog ab56299; Abcam); and Syrian hamster anti-podoplanin (1:200; 
8.1.1; Developmental Studies Hybridoma Bank). Sections were rinsed, 
blocked, and incubated in the dark for 90 minutes at room temperature 
with the following secondary antibodies from Jackson ImmunoRe-
search (1:200): donkey anti-rabbit Cy2 (catalog 711-225-152), donkey 
anti-rabbit Alexa Fluor 594 (catalog 711-585-152), donkey anti-chick-
en Alexa Fluor 647 (catalog 703-605-155), donkey anti-chicken 
Alexa Fluor 594 (catalog 703-585-155), donkey anti-rat Cy3 (catalog 
712-165-150), donkey anti-mouse Alexa Fluor 488 (catalog 715-545-
151), and goat anti-Syrian hamster FITC (catalog 107-095-142); and 
Hoechst 33258 (1:1,000; catalog B1155; Sigma-Aldrich). The Click-iT 
EdU Alexa Fluor 594 Kit (catalog C10339; Invitrogen, Thermo Fisher 
Scientific) was used according to the manufacturer’s instructions.
Imaging and image processing. Whole-mount tissue was imaged 
using a Leica MZ16FA dissecting stereoscope outfitted with a QIm-
aging Micropublisher 5.0 RTV color CCD camera. Paraffin-embed-
ded H&E- and X-gal–stained slides were imaged using a Leitz Dialux 
20 with a QImaging Micropublisher 5.0 RTV color CCD camera or 
an Olympus BX61 microscope equipped with a QImaging RETIGA 
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data analyzing more than 2 groups and biological replicate numbers of 
more than 10, a 1-way ANOVA with Kruskal-Wallis and Dunn’s mul-
tiple comparisons tests were used. The Mantel-Cox test was used to 
analyze Kaplan-Meier survival data. Patient-matched tumor and nor-
mal tissues were compared with a Wilcoxon matched-pairs t test and 
nonmatched tumors were compared using an unpaired Mann-Whit-
ney t test. All t tests were 2 tailed. A P value of less than 0.05 was con-
sidered statistically significant.
Study approval. All animal studies were conducted in accordance 
with protocols approved by the IACUC of the University of North Car-
olina at Chapel Hill.
Author contributions
DOK designed research studies, conducted experiments, acquired 
data, analyzed data, and wrote the manuscript. REB conducted 
mouse irradiation procedures and provided technical and intel-
lectual support. BZ conducted ex vivo culture experiments and 
provided technical and intellectual support. STE acquired data, 
provided technical and intellectual support, and edited the man-
uscript. ATM acquired data, provided technical and intellectual 
support, and edited the manuscript. MBS and CMP conducted 
bioinformatics analysis and provided technical support. SD pro-
vided reagents and intellectual support. STM designed research 
studies, acquired data, and provided reagents and intellectual 
support. PKL designed research studies and provided reagents 
and technical and intellectual support. KMC designed research 
studies, provided intellectual support, and edited the manuscript.
Acknowledgments
We thank the University of North Carolina Lineberger Animal 
Histopathology Core (NIH CA16086); the Center for Gastroin-
testinal Biology and Disease (NIH P30-DK34987); the Microsco-
py Services Laboratory; as well as Kirk McNaughton and Ashley 
Ezzell of the Histology Research Core. We also thank the current 
and past members of the Caron and Lund laboratories for discus-
sions. This work was supported by NIH grants RO1-HD060860 
and RO1-DK099156 (to KMC); NIH grant F31-CA174194 and a 
University of North Carolina Cell and Molecular Physiology Fell-
ner Fellowship (to DOK); NIH grant F31-DK107137 (to BZ); NIH 
grant 2-T32-DK07686 (to ATM); NIH grants 1-F30-CA200345 
and T32-CA071341-17 (to MBS); NIH grant P50-CA58223-09A1 
and a grant from the Breast Cancer Research Foundation (to 
CMP); NIH grant RO1-DK091427 (to STM); and NIH grant RO1-
DK040247-19 (to PKL).
Address correspondence to: Kathleen M. Caron, 111 Mason Farm 
Road, 6312B Medical Biomolecular Research Building, CB# 7545, 
Chapel Hill, North Carolina 27599, USA. Phone: 919.966.5193; 
E-mail: kathleen_caron@med.unc.edu.
Western blotting and analysis. Protein was extracted using Lens 
Homogenization Buffer with DTT and cOmplete Protease Inhib-
itor Cocktail Tablets (Roche) and a bead homogenizer (Percellys) 
according to standard procedures. Concentrations were determined 
using a Pierce bicinchoninic acid (BCA) protein assay kit (Thermo 
Fisher Scientific) read on a Mithras LB 940 Multimode Microplate 
Reader (Berthold Technologies). Protein was run on Mini-Protean 
TGX SDS-PAGE Gel (Bio-Rad Laboratories) and transferred onto a 
nitrocellulose (GE Healthcare) membrane. Blots were blocked and 
stained in 5% BSA diluted in TBS with 0.1% Tween-20. Blots were 
incubated overnight at 4°C with the following primary antibodies: 
rabbit anti-p42/44 MAPK (ERK1/2) (1:1,000; catalog 9102; Cell Sig-
naling Technology); rabbit anti–p-p42/44 MAPK (ERK1/2) (Thr202/
Tyr204) (1:1,000; catalog 9101; Cell Signaling Technology); rabbit 
anti-AKT (1:1,000; catalog 4691; Cell Signaling Technology); rabbit 
anti–p-AKT (Ser473) (1:2,000; catalog 4060; Cell Signaling Technol-
ogy); mouse anti–β-catenin (1:200; catalog 610153; BD Biosciences); 
rabbit anti-p38 MAPK (1:1,000; catalog 8690; Cell Signaling Tech-
nology); rabbit anti–p-p38 MAPK (Thr180/Tyr182) (1:1,000; catalog 
9211; Cell Signaling Technology); mouse anti-STAT3 (1:1,000; cata-
log 9139; Cell Signaling Technology); rabbit anti–p-STAT3 (Tyr705) 
(1:2,000; catalog 9145; Cell Signaling Technology); rabbit anti-YAP 
(1:1,000; catalog 14074; Cell Signaling Technology); rabbit anti– 
p-YAP (Ser127) (1:1,000; catalog 13008; Cell Signaling Technology); 
and mouse anti-GAPDH (1:5,000; catalog NB300-285; Novus Biolog-
icals). Blots were rinsed, blocked in 5% nonfat milk, and incubated in 
the dark for 60 minutes at room temperature with the following sec-
ondary antibodies: goat anti-rabbit DyLight 680 (1:12,000; catalog 
35568; Thermo Fisher Scientific) and goat anti-mouse DyLight 800 
(1:12,000; catalog SA5-10176; Thermo Fisher Scientific). An Odyssey 
CLx (LI-COR Biosciences) was used for imaging. Image brightness 
and contrast changes were made equally across all comparable imag-
es using Image Studio and Adobe Photoshop CS4. Phosphorylated 
and total protein quantification was analyzed by densitometry using 
ImageJ and normalized to Gpr182+/+ controls. GAPDH was used to 
ensure equal loading.
RNA-seq analysis. RNA-seq data were downloaded from the TCGA 
Data Portal (44, 45). RSEM upper-quantile–normalized values from 
Illumina HiSeq _RNASeqV2 from patient-matched tumor and normal 
tissue were log2 transformed. Samples with an expression value of 3 or 
lower were indistinguishable from background values and were thus 
considered a 0 value.
Statistics. Statistical analysis was performed with GraphPad Prism 
5.0 (GraphPad Software), and all data are represented as the mean ± 
SEM. The unpaired or Mann-Whitney t test was used for data analysis 
of 2 groups with biological replicate numbers of less than 10 or more 
than 10, respectively. For parametric data with more than 2 compari-
sons and biological replicate numbers of less than 10, a 1-way ANOVA 
with Tukey’s multiple comparisons test were used. For nonparametric 
 1. Rask-Andersen M, Almen MS, Schioth HB. 
Trends in the exploitation of novel drug targets. 
Nat Rev Drug Discov. 2011;10(8):579–590.
 2. Civelli O, Reinscheid RK, Zhang Y, Wang Z, 
Fredriksson R, Schioth HB. G protein-coupled 
receptor deorphanizations. Annu Rev Pharmacol 
Toxicol. 2013;53:127–146.
 3. Harrison JK, Barber CM, Lynch KR. Molecular 
cloning of a novel rat G-protein-coupled receptor 
gene expressed prominently in lung, adrenal, 
and liver. FEBS Lett. 1993;318(1):17–22.
 4. Kapas S, Catt KJ, Clark AJ. Cloning and expression 
of cDNA encoding a rat adrenomedullin receptor. 
J Biol Chem. 1995;270(43):25344–25347.
 5. Kennedy SP, Sun D, Oleynek JJ, Hoth CF, Kong 
J, Hill RJ. Expression of the rat adrenomedullin 
receptor or a putative human adrenomedullin 
receptor does not correlate with adrenomedullin 
binding or functional response. Biochem Biophys 
Res Commun. 1998;244(3):832–837.
 6. McLatchie LM, et al. RAMPs regulate the 
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
6 0 6 jci.org   Volume 127   Number 2   February 2017
transport and ligand specificity of the cal-
citonin-receptor-like receptor. Nature. 
1998;393(6683):333–339.
 7. Ramachandran V, Arumugam T, Hwang RF, 
Greenson JK, Simeone DM, Logsdon CD. Adre-
nomedullin is expressed in pancreatic cancer and 
stimulates cell proliferation and invasion in an 
autocrine manner via the adrenomedullin recep-
tor, ADMR. Cancer Res. 2007;67(6):2666–2675.
 8. Ramachandran V, et al. The ADMR recep-
tor mediates the effects of adrenomedullin 
on pancreatic cancer cells and on cells of 
the tumor microenvironment. PLoS One. 
2009;4(10):e7502.
 9. Regard JB, Sato IT, Coughlin SR. Anatomical pro-
filing of G protein-coupled receptor expression. 
Cell. 2008;135(3):561–571.
 10. Takase H, et al. Genome-wide identification of 
endothelial cell-enriched genes in the mouse 
embryo. Blood. 2012;120(4):914–923.
 11. Xiao L, Harrell JC, Perou CM, Dudley AC. 
Identification of a stable molecular signature in 
mammary tumor endothelial cells that persists in 
vitro. Angiogenesis. 2014;17(3):511–518.
 12. Sumanas S, Jorniak T, Lin S. Identification of 
novel vascular endothelial-specific genes by 
the microarray analysis of the zebrafish cloche 
mutants. Blood. 2005;106(2):534–541.
 13. Alghisi E, et al. Targeting oncogene expression 
to endothelial cells induces proliferation of the 
myelo-erythroid lineage by repressing the Notch 
pathway. Leukemia. 2013;27(11):2229–2241.
 14. Clevers H. The intestinal crypt, a prototype stem 
cell compartment. Cell. 2013;154(2):274–284.
 15. Barker N. Adult intestinal stem cells: critical driv-
ers of epithelial homeostasis and regeneration. 
Nat Rev Mol Cell Biol. 2014;15(1):19–33.
 16. Gracz AD, Magness ST. Defining hierarchies of 
stemness in the intestine: evidence from bio-
markers and regulatory pathways. Am J Physiol 
Gastrointest Liver Physiol. 2014;307(3):G260–273.
 17. Chia LA, Kuo CJ. The intestinal stem cell. Prog 
Mol Biol Transl Sci. 2010;96:157–173.
 18. Van Landeghem L, et al. Activation of two dis-
tinct Sox9-EGFP-expressing intestinal stem 
cell populations during crypt regeneration after 
irradiation. Am J Physiol Gastrointest Liver Physiol. 
2012;302(10):G1111–1132.
 19. Barker N, et al. Identification of stem cells in 
small intestine and colon by marker gene Lgr5. 
Nature. 2007;449(7165):1003–1007.
 20. Powell AE, et al. The pan-ErbB negative reg-
ulator Lrig1 is an intestinal stem cell marker 
that functions as a tumor suppressor. Cell. 
2012;149(1):146–158.
 21. van der Flier LG, et al. Transcription factor 
achaete scute-like 2 controls intestinal stem cell 
fate. Cell. 2009;136(5):903–912.
 22. van der Flier LG, Haegebarth A, Stange DE, van 
de Wetering M, Clevers H. OLFM4 is a robust 
marker for stem cells in human intestine and 
marks a subset of colorectal cancer cells. Gastro-
enterology. 2009;137(1):15–17.
 23. Takeda N, Jain R, LeBoeuf MR, Wang Q, Lu MM, 
Epstein JA. Interconversion between intestinal 
stem cell populations in distinct niches. Science. 
2011;334(6061):1420–1424.
 24. Sangiorgi E, Capecchi MR. Bmi1 is expressed 
in vivo in intestinal stem cells. Nat Genet. 
2008;40(7):915–920.
 25. Formeister EJ, Sionas AL, Lorance DK, Barkley 
CL, Lee GH, Magness ST. Distinct SOX9 levels 
differentially mark stem/progenitor populations 
and enteroendocrine cells of the small intestine 
epithelium. Am J Physiol Gastrointest Liver Physiol. 
2009;296(5):G1108–1118.
 26. Montgomery RK, et al. Mouse telomerase reverse 
transcriptase (mTert) expression marks slowly 
cycling intestinal stem cells. Proc Natl Acad Sci  
U S A. 2011;108(1):179–184.
 27. Scoville DH, Sato T, He XC, Li L. Current view: 
intestinal stem cells and signaling. Gastroenterol-
ogy. 2008;134(3):849–864.
 28. Barker N, et al. Crypt stem cells as the 
cells-of-origin of intestinal cancer. Nature. 
2009;457(7229):608–611.
 29. UC Davis. Knockout Mouse Project (KOMP) 
Respository. https://www.komp.org. Accessed 
November 30, 2016.
 30. Gracz AD, Ramalingam S, Magness ST. Sox9 
expression marks a subset of CD24-expressing 
small intestine epithelial stem cells that form 
organoids in vitro. Am J Physiol Gastrointest Liver 
Physiol. 2010;298(5):G590–G600.
 31. Gracz AD, et al. A high-throughput platform 
for stem cell niche co-cultures and down-
stream gene expression analysis. Nat Cell Biol. 
2015;17(3):340–349.
 32. Roche KC, Gracz AD, Liu XF, Newton V, Aki-
yama H, Magness ST. SOX9 maintains reserve 
stem cells and preserves radioresistance 
in mouse small intestine. Gastroenterology. 
2015;149(6):1553–1563.e10.
 33. Yan KS, et al. The intestinal stem cell mark-
ers Bmi1 and Lgr5 identify two functionally 
distinct populations. Proc Natl Acad Sci U S A. 
2012;109(2):466–471.
 34. Hua G, et al. Crypt base columnar stem cells in 
small intestines of mice are radioresistant. Gas-
troenterology. 2012;143(5):1266–1276.
 35. Metcalfe C, Kljavin NM, Ybarra R, de Sauvage 
FJ. Lgr5+ stem cells are indispensable for radia-
tion-induced intestinal regeneration. Cell Stem 
Cell. 2014;14(2):149–159.
 36. Moser AR, Pitot HC, Dove WF. A domi-
nant mutation that predisposes to multiple 
intestinal neoplasia in the mouse. Science. 
1990;247(4940):322–324.
 37. Morin PJ, et al. Activation of beta-catenin-Tcf sig-
naling in colon cancer by mutations in beta-catenin 
or APC. Science. 1997;275(5307):1787–1790.
 38. Kozar S, et al. Continuous clonal labeling reveals 
small numbers of functional stem cells in 
intestinal crypts and adenomas. Cell Stem Cell. 
2013;13(5):626–633.
 39. Nakanishi Y, et al. Dclk1 distinguishes between 
tumor and normal stem cells in the intestine. Nat 
Genet. 2013;45(1):98–103.
 40. Gracz AD, et al. Brief report: CD24 and CD44 
mark human intestinal epithelial cell populations 
with characteristics of active and facultative stem 
cells. Stem Cells. 2013;31(9):2024–2030.
 41. Wang F, et al. Isolation and characterization of 
intestinal stem cells based on surface marker 
combinations and colony-formation assay. Gas-
troenterology. 2013;145(2):383–95.e1.
 42. Sato T, et al. Single Lgr5 stem cells build crypt-vil-
lus structures in vitro without a mesenchymal 
niche. Nature. 2009;459(7244):262–265.
 43. de Jong PR, et al. ERK5 signalling rescues intes-
tinal epithelial turnover and tumour cell prolif-
eration upon ERK1/2 abrogation. Nat Commun. 
2016;7:11551.
 44. Hoadley KA, et al. Multiplatform analysis of 
12 cancer types reveals molecular classifica-
tion within and across tissues of origin. Cell. 
2014;158(4):929–944.
 45. National Institute of Health National Cancer Insti-
tute National Human Genome Research Institute. 
The Cancer Genome Atlas (TCGA) Data Portal. 
https://tcga-data.nci.nih.gov/docs/publications/
tcga/?. Accessed November 30, 2016.
 46. Noah TK, et al. SPDEF functions as a colorectal 
tumor suppressor by inhibiting β-catenin activity. 
Gastroenterology. 2013;144(5):1012–1023.e6.
 47. Bossuyt W, et al. Atonal homolog 1 is a tumor sup-
pressor gene. PLoS Biol. 2009;7(2):e39.
 48. Depeille P, et al. RasGRP1 opposes prolifer-
ative EGFR-SOS1-Ras signals and restricts 
intestinal epithelial cell growth. Nat Cell Biol. 
2015;17(6):804–815.
 49. Nam KT, et al. Loss of Rab25 promotes the devel-
opment of intestinal neoplasia in mice and is 
associated with human colorectal adenocarcino-
mas. J Clin Invest. 2010;120(3):840–849.
 50. Espersen ML, Olsen J, Linnemann D, Høgdall E, 
Troelsen JT. Clinical implications of intestinal 
stem cell markers in colorectal cancer. Clin Col-
orectal Cancer. 2015;14(2):63–71.
 51. Lee SH, et al. ERK activation drives intestinal 
tumorigenesis in Apc(min/+) mice. Nat Med. 
2010;16(6):665–670.
 52. Roberts RB, et al. Importance of epidermal 
growth factor receptor signaling in establishment 
of adenomas and maintenance of carcinomas 
during intestinal tumorigenesis. Proc Natl Acad 
Sci U S A. 2002;99(3):1521–1526.
 53. Wong VW, et al. Lrig1 controls intestinal stem-
cell homeostasis by negative regulation of ErbB 
signalling. Nat Cell Biol. 2012;14(4):401–408.
 54. Sansom OJ, et al. Loss of Apc allows phenotypic 
manifestation of the transforming properties of 
an endogenous K-ras oncogene in vivo. Proc Natl 
Acad Sci USA. 2006;103(38):14122–14127.
 55. Dow LE, et al. Apc restoration promotes cellular 
differentiation and reestablishes crypt homeostasis 
in colorectal cancer. Cell. 2015;161(7):1539–1552.
 56. Phelps RA, et al. A two-step model for colon ade-
noma initiation and progression caused by APC 
loss. Cell. 2009;137(4):623–634.
 57. Haigis KM, et al. Differential effects of oncogenic 
K-Ras and N-Ras on proliferation, differentiation 
and tumor progression in the colon. Nat Genet. 
2008;40(5):600–608.
 58. Janssen KP, et al. APC and oncogenic KRAS are 
synergistic in enhancing Wnt signaling in intesti-
nal tumor formation and progression. Gastroen-
terology. 2006;131(4):1096–1109.
 59. Yu FX, et al. Regulation of the Hippo-YAP path-
way by G-protein-coupled receptor signaling. 
Cell. 2012;150(4):780–791.
 60. Prenzel N, et al. EGF receptor transactivation 
by G-protein-coupled receptors requires metal-
loproteinase cleavage of proHB-EGF. Nature. 
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
6 0 7jci.org   Volume 127   Number 2   February 2017
1999;402(6764):884–888.
 61. Wilson CH, McIntyre RE, Arends MJ, Adams DJ. 
The activating mutation R201C in GNAS promotes 
intestinal tumourigenesis in Apc(Min/+) mice 
through activation of Wnt and ERK1/2 MAPK 
pathways. Oncogene. 2010;29(32):4567–4575.
 62. Testa G, et al. A reliable lacZ expression reporter 
cassette for multipurpose, knockout-first alleles. 
Genesis. 2004;38(3):151–158.
 63. Bradley A, et al. The mammalian gene function 
resource: the International Knockout Mouse Con-
sortium. Mamm Genome. 2012;23(9-10):580–586.
 64. Yin X, Farin HF, van Es JH, Clevers H, Langer R, 
Karp JM. Niche-independent high-purity cultures 
of Lgr5+ intestinal stem cells and their progeny. 
Nat Methods. 2014;11(1):106–112.
 65. Karpinich NO, Kechele DO, Espenschied ST, 
Willcockson HH, Fedoriw Y, Caron KM. Adre-
nomedullin gene dosage correlates with tumor 
and lymph node lymphangiogenesis. FASEB J. 
2013;27(2):590–600.
 66. Andres SF, Simmons JG, Mah AT, Santoro MA, 
Van Landeghem L, Lund PK. Insulin receptor 
isoform switching in intestinal stem cells, pro-
genitors, differentiated lineages and tumors: 
evidence that IR-B limits proliferation. J Cell Sci. 
2013;126(Pt 24):5645–5656.
